Scleroderma
2 papers
- Humans1
Trial sponsors
Company1 trialPhase 380 people
Company1 trialPhase 2/337 people
Company1 trialPhase 1/247 people
1 trialPhase 4240 people
Post Graduate Institute of Medical Education and Research, Chandigarh
1 trialPhase 341 people
Assistance Publique - Hôpitaux de Paris
1 trialPhase 340 people
1 trialPhase 36 people
2 trialsPhase 2/318 people
Latest
4 in 12 monthsArthritis & Rheumatology
Down-Regulated Fli1 in Scleroderma Myeloid Cells Contributes to Cardiac Fibrosis Via a Galectin-3/mTOR Dependent Pathway
Experiments in micemTOR signalling
Stem Cells Translational Medicine
MSCs derived from ADSC-reprogrammed iPSCs exhibit enhanced therapeutic potential for treating skin fibrosis
Experiments in miceSkin
AHA Scientific Sessions 2025 Abstract
Refining Atherosclerotic Risk Prediction in Patients with Systemic Sclerosis: Association with Uric Acid and the Creation of a Novel Scleroderma-Atherosclerotic Cardiovascular Disease Risk (ScleroRisk) Assessment Model
Cohort study of 551 peopleUric acid
Aging
National survey of Hutchinson-Gilford progeria syndrome and progeroid laminopathy in Japan
Cross-sectional study of 10 peopleProgeria
ADA Scientific Sessions 2025 Abstract
Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial
Randomised trial in 3,533 peopleSemaglutide
International Journal of Molecular Sciences
Markers of Type 2 Inflammation and Immunosenescence Are Upregulated in Localized Scleroderma
Computational studyMechanisms